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The role of CFTR deficiency in promoting inflammation remains unclear. Perez et al. [A. Perez, A.C. Issler, C.U. Cotton, T.J. Kelley, A.S.
Verkman and P.B. Davis, CFTR inhibition mimics the cystic fibrosis inflammatory profile. Am J Physiol Lung Cell Mol Physiol 2007; 292:L383–
L395.] recently demonstrated that the inhibition of function of w/t CFTR produces an inflammatory profile that resembles that observed in CF
patients, whereas we found that correction of F508del-CFTR function with MPB-07 down-modulates the inflammatory response to P. aeruginosa
in CF bronchial cells [M.C. Dechecchi, E. Nicolis, V. Bezzerri, A. Vella, M. Colombatti, B.M. Assael, et al., MPB-07 reduces the inflammatory
response to Pseudomonas aeruginosa in cystic fibrosis bronchial cells. Am J Respir Cell Mol Biol 2007; 36, 615–624.]. Since both evidence
support a link between CFTR function and inflammation, we extended our investigation to other F508del-CFTR correctors, such as miglustat
(Norez, 2006), an approved drug for Gaucher disease, in comparison with the galactose analogue NB-DGJ. We report here that miglustat but not
NB-DGJ restores F508del-CFTR function in CF bronchial epithelial IB3-1 and CuFi-1 cells. Miglustat and NB-DGJ reduce the inflammatory
response to P. aeruginosa in both CF and non-CF bronchial cells, indicating that the anti-inflammatory effect is independent of the correction of
F508del-CFTR function. Miglustat also inhibits the inflammatory response induced by the supernatant of mucopurulent material obtained from the
lower airway tract of cystic fibrosis patients with chronic bacterial colonization (Ribeiro, 2005). Both compounds do not interfere with the
adherence of P. aeruginosa to the cells and reduce the expression of IL-8 not only after challenge with P. aeruginosa but also after exposure to
TNF alpha or IL-1 beta, suggesting an effect on transduction proteins downstream and in common with different receptors for pathogens. Finally,
miglustat has no major effects on overall binding activity of transcription factors NF-κBNF-kB and AP-1. Since miglustat is an approved drug, it
could be investigated as a novel anti-inflammatory molecule to ameliorate lung inflammation in CF patients.
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Airway epithelial cells have their own repertoire of innate
immune functions. Once pathogens invade the airways, the
epithelium expresses chemokines and cytokines to recruit and
activate neutrophils, thus contributing to initiate the overall
inflammatory response in the lung. Airway inflammation is a
hallmark of cystic fibrosis (CF) lung disease that is character-
ized by persistent bacterial infection, prevalently by Pseudo-
monas aeruginosa (P. aeruginosa), increased number of
neutrophils and elevated levels of cytokines in the airwayd by Elsevier B.V. All rights reserved.
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response to infection is dysregulated and excessive, however it
remains enigmatic how abnormalities in the cystic fibrosis
transmembrane conductance regulator (CFTR) can be responsible
for the exuberant and persistent pulmonary infection and
inflammation. The most prominent hypotheses propose that
defective CFTR causes a decrease in the airway surface liquid
(ASL) which makes more difficult to efficiently clear infected
secretions from the lung [4], leading to a chronic obstruction and
bacterial infection with Gram-negative organisms growing in
biofilms, especially P. aeruginosa, thus triggering a dramatic
inflammatory response. It has been controversial whether this
hyperinflammatory milieu is only the result of the chronic
infection or it is primary to the CFTR defect [5]. This controversy
is difficult to resolve since most of the studies have been
performed comparing cell cultures developed from normal and
CF individuals which differ at many genetic loci besides the CF
gene, thus increasing the variability and making unlikely to
ascribe responses only to defective CFTR. Recently, the CFTR-
specific inhibitor CFTRinh-172was used byPerez et al., to create a
CF model with its own control to test whether the absence of
CFTR-dependent Cl-conductance by itself was sufficient to
produce inflammatory changes observed inmatched cell lines [7].
They demonstrated that the inhibition of function of CFTR
mimics the CF inflammatory profile, supporting the hypothesis
that lack of CFTR activity accounts for the onset of the
inflammatory cascade in the CF lung. On the other hand, we
have previously shown that in CF bronchial cells, the correction
of F508del-CFTR function with the corrector benzo(c)quinolizi-
nium (MPB)-07 strongly reduces the inflammatory response
induced by P. aeruginosa [8]. These complementary lines of
evidence suggest that the pro-inflammatory circuitry in CF
airways could be initiated from those surface epithelial cells
lacking CFTR function. Therefore, in the present work we have
further explored the possibility to control the inflammatory
response to P. aeruginosa in CF bronchial cells through the
pharmacological modulation of CFTR defect. These studies are in
line with the concept that knowledge of the pharmacotherapy for
defective CFTR is on an exponential increase as high-throughput
screening of chemically different compounds is revealing a great
number of activators [6,9,10] and correctors of defective
processing [10–12].
In this respect, glycosidases are involved in the biosynthesis of
the oligosaccharide chains and quality control mechanisms of the
N-linked glycoproteins and glycolipids and have been implicated
in the development of various diseases including viral infection,
cancer and genetic disorders [13]. The iminosugar N-butyldeox-
ynojirimycin (miglustat), an inhibitor of glycolipid biosynthesis
[14] as been proposed for treating type I Gaucher disease, an
inherited glycosphingolipid (GSL) lysosomal storage disease
[15]. In addition to the inhibitory effect on the glycolipid biosyn-
thesis, miglustat is a potent α-glucosidase inhibitor and may also
works as a pharmaceutical chaperone [16].
We have recently demonstrated that miglustat restores
functional F508del-CFTR channels in human and mice epithelial
CF cells [17]. There is no information regarding the effects of
miglustat on the inflammatory response in CF epithelial cells.In the present study, airway inflammatory response to P.
aeruginosa was investigated by measuring the expression of
interleukin (IL)-8 and intercellular adhesionmolecule-1 (ICAM-
1) induced by the P. aeruginosa laboratory strain PAO1 in CF
bronchial cells treated with miglustat, in comparison with the
galactose analogue N-butyldeoxygalactonojirimycin (NB-
DGJ). The effect of miglustat was also studied in CF cells
stimulated by pooled supernatants of mucopurulent material
(SMM) collected from the lower airway tract of the lungs of CF
patients with chronic bacterial colonization obtained at the time
of lung transplantation [18–19]. In addition to IB3-1 and CuFi-1,
the possible anti-inflammatory effect of miglustat was analyzed
in non-CF NuLi-1 cells. The effects of miglustat on the
expression of IL-8 and ICAM-1 were compared with the
analysis of the activity of two transcription factors (NF-κB and
AP-1).
Since miglustat is an approved drug, it could represent an
interesting new molecule to ameliorate lung inflammation in CF
patients. Therefore, analysis of its effects on bronchial CF and
non-CF cells is mandatory to reach a general commitment about
the use of miglustat in novel therapeutic approaches based on
ability to restore functional CFTR channels and to reduce
inflammation.
2. Methods
2.1. Cell lines and bacteria
IB3-1 is a human bronchial epithelial cell line, immortalised
with adeno12/SV40, derived from a CF patient with a F508del/
W1282X mutant genotype [20]. These cells have been obtained
from LGC Promochem, Europe and were grown in LHC-8 basal
medium (Biofluids Inc., Rockville, MO) supplemented with 5%
FBS. All culture flasks and plates were coated with a solution
containing 35 μg/ml bovine collagen (Becton–Dickinson,
Franklin Lakes, NJ), 1 μg/ml BSA (Sigma, St. Louis, MO)
and 1 μg/ml human fibronectin (Becton–Dickinson) as
described [20]. CuFi-1 and NuLi-1 cells, a generous gift of A.
Klingelhutz, P. Karp and J. Zabner (University of Iowa, Iowa
City) derived from human bronchial epithelium from a CF
patient (CuFi-1, F508del/F508del CFTR mutant genotype) or a
non-CF subject (NuLi-1, wild type CFTR) and have been
transformed by the reverse transcriptase component of telomer-
ase, hTERT, and human papillomavirus type 16 (HPV-16) E6
and E7 genes [21]. These cell lines were grown on human
placental collagen type VI (Sigma, St. Louis, MO) coated flasks
in BEGM medium (Cambrex Bio Science Walkersville, MD),
as described [20]. PAO1, a prototypic laboratory strain of P.
aeruginosa, kindly provided by A. Prince (Columbia Uni-
versity, NewYork) was grown in trypticase soy broth (TSB) or
agar (TSA) (Difco, Detroit MI).
2.2. CFTR function assay
2.2.1. Single-cell fluorescence imaging
IB3-1 and CuFi-1 cells were incubated with 200 μM
miglustat or NB-DGJ (Toronto Research Chemicals, North
557M.C. Dechecchi et al. / Journal of Cystic Fibrosis 7 (2008) 555–565York, ON,Canada) for 2, 4 and 24 h.CFTR functionwas assessed
by single-cell fluorescence imaging, using the potential-sensitive
probe DiSBAC2[3] (Molecular Probes, Eugene, OR) as pre-
viously reported [8]. CFTR-dependent Cl-channel was stimulated
by a cAMP elevating cocktail: 20 μM forskolin plus 100 μM
IBMX and 50 μM genistein. The thiazolidinone CFTR inhibitor
CFTRinh-172, kindly provided by A. S.Verkman (University of
California, San Francisco) [22], was added to a final concentration
of 10 μM.2.2.2. Iodide efflux
CuFi-1 cells were grown in multiwell plates and incubated
with miglustat ranging from 1 nM to 100 μM for 24 h. Iodide
efflux was performed as described [23]. Cells cultured in
multiwell plates were washed twice with efflux buffer containing
(in mM) 136.9 NaCl, 5.4 KCl, 0.3 KH2PO4, 0.3 NaH2PO4, 1.3
CaCl2, 0.5 MgCl2, 0.4 MgSO4, 5.6 glucose and 10 HEPES, pH
7.4 and incubated in efflux buffer containing Na125I (1 μCi
Na125I/ml, NEN, Boston, MA) during 1 h at 37 °C. Cells were
thenwashedwith effluxmedium to remove extracellular 125I. The
loss of intracellular 125I was determined by removing the medium
with efflux buffer every 1 min for up to 10 min. The first three
aliquots were used to establish a stable baseline in efflux buffer
alone. Amedium containing the appropriate drugwas used for the
remaining aliquots. Residual radioactivity was extracted with
0.1 N NaOH/0.1% SDS. The fraction of initial intracellular 125I
lost during each time point was collected and time-dependent
rates of 125I efflux calculated from: ln(It1
125It1 /
125It2) / (t1− t2)
where 125It is the intracellular
125I at time t, and t1 and t2
successive time points. Curves were constructed by plotting rate
of 125I versus time. All comparisons were based on maximal
values for the time-dependent rates (k=peak rates, min−1)
excluding the points used to establish the baseline (k peak–k
basal, min−1). The rate of activation was determined after
mathematical fitting. The EC50 was calculated using the software
GraphPad Prism version 4.0 for Windows (Graphpad Software).
2.3. Inflammatory response
Cells were seeded at density ranging from 50,000 to 100,000
cells/cm2. After adhesion, IB3-1 cells were starved in serum
free LHC-8 for 18 h. Before the experiment, bacteria from
overnight cultures on TSA plates were grown in 20 ml TSB
broth at 37 °C with shaking until there was an OD at 660 nm of
about 1×109 CFU/ml, determined by dilution plating. Mono-
layers of cells were treated or not with 200 μMmiglustat or NB-
DGJ, dissolved in water, for 24 h and then infected with PAO1
as described [8], or stimulated by the pro-inflammatory
cytokines TNF alpha [10 ng/ml] or IL-1 beta [50 ng/ml]
(Human recombinant, Sigma, St. Louis, MO), for 4 h at 37 °C.
Monolayer of cells were incubated for 4 h with supernatants of
mucopurulent material (SMM) pooled from samples collectedFig. 1. Miglustat restores F508del-CFTR function in IB3-1 and CuFi-1
bronchial cells. IB3-1 cells grown on round glass coverslips were incubated with
miglustat or NB-DGJ (200 μM) for 2 and 4 h (A) or 24 h (B) and then mounted
on the perfusion chamber and perfused with Cl-free solution containing
DiSBAC2 [3] to allow the equilibration of the dye within cell membranes. The
arrows indicate the time of the addition of the stimuli or the inhibitor.
Fluorescence coming from each single cell was analyzed. Typical time courses
are shown. Data represents the mean±SEM of the relative fluorescence
collected from all the cells of the field (n=9 A, n=11 B). Representative of 6 (A)
or 4 (B) independent experiments are shown C. CuFi-1 cells grown on round
glass coverslips were incubated with miglustat or NB-DGJ as indicated for A
and B and then mounted on the perfusion chamber and the experiment
performed as indicated above. Data represents the mean±SEM of the relative
fluorescence collected from all the cells of the field (n=9). Representative of 6
independent experiments is shown.
Fig. 2. Dose–response of rescue of F508del-CFTR function by miglustat in
CuFi-1 cells. Cells seeded on multiwell plates were treated for 24 h with various
concentration of miglustat. A. Example of mean traces showing the restoration
of an iodide efflux on CuFi-1 cells treated 24 h with various concentration of
miglustat and stimulated by a cAMP cocktail (forskolin 20 μM+IBMX
100 μM)+genistein 50 μM. B. Concentration–response curve showing CFTR-
dependent iodide efflux at each miglustat concentration. n=4 for each
concentration.
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aeruginosa and Staphylococcus aureus, obtained as described
[18–19], from lungs at the time of transplantation, diluted 1:25
in medium. The expression of mRNA of IL-8 and ICAM-1 was
measured by Real-time qPCR as described [8].
2.4. Electrophoretic mobility shift assay (EMSA)
Cells were seeded on coated Petri dishes (5 cm diameter) at
density of 100,000/cm2 24 h before infection, infected as
described above for 2 h and detached by trypsin. DNA-binding
proteins were extracted by hypotonic lysis followed by high salt
extraction of nuclei [24]. EMSA was perfomed as previously
described [25]. Briefly, double-stranded synthetic oligodeox-
ynucleotides mimicking the NF-κB and the AP-1 binding sites
(NF-κB, sense: 5′-AATCGTGGAATTTCCTCT-3′, AP-1
sense: 5′-TGTGATGACTCAGGTTTG-3′) have been
employed. Oligodeoxynucleotides were labeled with γ32-P-
ATP using 10 Units of T4-polinucleotide-kinase (MBI Fermen-
tas) in 500 mM Tris–HCl, pH 7.6, 100 mM MgCl2, 50 mM
DTT, 1 mM spermidine, 1 mM EDTA in the presence of 50 μCi
γ32-P-ATP) in a volume of 20 μl for 45 min at 37 °C. Reaction
was brought to 150 mM NaCl and 150 ng complementary
oligodeoxynucleotide was added. Reaction temperature was
increased to 100 °C for 5 min and left diminishing to room
temperature overnight. Nuclear extracts from cells were used at
concentrations ranging from 0.5 to 2 μg/reaction concentrations
in the presence of poly (dI:dC) (1 mg/reaction) to abolish non-
specific binding. After 25 min binding at room temperature, the
samples were run at constant voltage (200 V) under low ionic
strength conditions (0.25× TBE buffer: 22 mM Tris-borate,
0.4 mM EDTA) on 6% polyacrylamide gels. Gels were dried
and subjected to standard autoradiographic procedures.
2.5. Adherence of PAO1 to IB3-1 and CuFi-1 cells
PAO1 were metabolically labelled with [35S] methionine
according to [26] with minor changes. Colonies of PAO1 from
overnight TSA plates were inoculated in 20 ml M9 medium and
grown at 37 °C with shaking to a density of 108 CFU/ml. M9
medium (Difco, Detroit MI) was used to have high-specific
activity labelling. 100 μCi/ml [35 S] methionine (Amersham
Biosciences, Uppsala, Sweden) was added to the broth and
incubated at 37 °C with shaking for 30 min. Bacteria were then
washed twice with 10 mM NaCl and resuspended in PBS.
Aliquots of the bacterial suspension were plated and scintilla-
tions counted to calculate the number of bacteria associated with
the counts per minute (CFU/cpm). Specific activity ranged
between 40 and 1000 CFU/cpm.
Metabolically labelled PAO1 were added to monolayers of
IB3-1 or CuFi-1 cells, in duplicate, and incubated at room
temperature for 60 min. Unbound organisms were rinsed off the
monolayers with three successive PBS washes. Cells and
adherent bacteria were solubilized in 0.5 ml of 2% SDS and
scintillations were counted. Specific binding was calculated by
subtracting counts obtained in the presence of 100-fold excess
unlabelled PAO1. Non-specific binding was about 30% of total.2.6. Statistics
Results are expressed as mean±standard error of the mean.
Comparisons between groups were made by using Student's t
test and a one-way analysis of variance (ANOVA). Statistical
significance was defined with pb0.05.
3. Results
3.1. Functional evaluation of CFTR in airway epithelial cells
treated with miglustat
We have previously demonstrated that the treatment for 2 h
with miglustat restores the CFTR-dependent Cl-transport in
human nasal epithelial JME/CF15, tracheal gland serous CF-
KM4, pancreatic duct CFPAC-1 cell lines and intestinal cells of
F508del-CFTR mice [17]. Therefore CFTR function was tested
here in bronchial IB3-1 and CuFi-1 cell lines treated with
miglustat or with NB-DGJ. IB3-1 cells were incubated for 2, 4
and 24 h in the presence of 200 μM miglustat or NB-DGJ. As
shown in Fig. 1, the fluorescence signal does not change in
untreated cells or in cells treated with NB-DGJ, whereas the
addition of the cAMP stimulation cocktail plus genistein
increases the fluorescence after 2 and, more evidently, 4 h
treatment with miglustat. The sharp decrease observed after the
addition of CFTRinh-172 indicates the CFTR-specific functional
Fig. 3. Miglustat reduces the expression of mRNA of IL-8 and ICAM-1, stimulated by PAO1 in IB3-1 and CuFi-1 cells. Cells were incubated for 24 h in the presence of
200 μM miglustat and infected with PAO1 (50 CFU/cell) for 4 h as described in the Materials and methods section. The mRNA induction (relative to non-
infected cells) is obtained by comparing the ratio IL-8/GAPDH (A, C) and ICAM-1/GAPDH (B,D) between non-infected and infected cells. Results are expressed as
mean±SEM of duplicate wells. Representative of 9 independents experiments (A) or 6 (B, C and D) in duplicate are shown.
Fig. 4. Miglustat inhibits the inflammatory response to SMM in IB3-1 cells.
Cells were incubated for 24 h in the presence of 200 μM miglustat and then
stimulated by SMM diluted 1:25 in medium, for 4 h. The IL-8 mRNA induction
(relative to not infected cells) is obtained as indicated in the legend of Fig. 3.
Results are expressed as mean±SEM of duplicate wells. Representative of 2
independent experiments, in duplicate, is shown.
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no correction is observed after 24 h of treatment with miglustat
(Fig. 1B). The results obtained in CuFi-1 cells are reported in
Fig. 1C. In agreement with IB3-1 cells, no changes of the
fluorescent signal are obtained in untreated cells or in cells
treated with NB-DGJ. As demonstrated by the increase of the
fluorescence after the addition of the cAMP stimulation cocktail
plus genistein and by the decrease after the addition of the
inhibitor, a correction of F508del-CFTR function is observed
after 2, 4 and more evident, 24 h of treatment. Collectively,
these results indicate a fast rescue of F508del-CFTR function
both in IB3-1 and CuFi-1 CF cells.
In order to evaluate the half maximal effective concentration
of miglustat, CFTR-dependent Cl-transport was studied in
CuFi-1 cells by iodide efflux. Cells were incubated in the
presence of miglustat ranging from 1 nM to 100 μM and iodide
efflux was performed as described above. Fig. 2A shows the
correction of CFTR function by miglustat in CuFi-1 cells
starting from 10 nM, being 76 nM the half maximal effective
concentration (Fig. 2B).
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mediators in IB3-1 cells and CuFi-1 cells stimulated by PAO1
The principal aim of this study was to evaluate the effect of
correctors of F508del-CFTR function on the modulation of the
expression of pro-inflammatory mediators, induced by P.
aeruginosa infection in respiratory epithelial cells. IL-8 is an
essential component of the host defense system, being released
from respiratory epithelial cells in response to bacteria, to
regulate transepithelial migration and activation of neutrophils
[27]. ICAM-1 is constitutively expressed on the cell surface of a
wide variety of cells and it is modulated in response to differentFig. 5. A. Increase of NF-κB and AP-1 binding activity following PAO1 infection. Nu
amounts (μg/reactions) of nuclear proteins were mixed with 32P-labelled NF-κB and A
gel-shift. Asterisks indicate free 32P-labelled NF-κB and AP-1 probes. B,C. Miglustat
cultured in the absence (upper gels in each panel) or in the presence (lower gels in each
PAO1 for 2 h, as indicated. Nuclear extracts from these treated cells, as indicated, we
κBNF-kB (B) and AP-1 (C) target 32P-labelled oligodeoxynucleotides and EMSA per
interactions obtained using 0.5 μg /reaction nuclear factors, performed using the B
binding activities relative to control protein extracts isolated from untreated contro
miglustat, no PAO1; grey bars: miglustat; black bars: PAO1; dashed bars: PAO1+minflammatory stimuli, including bacteria [28]. As we have
previously demonstrated that overnight incubation of CF
bronchial cells with the corrector MPB-07 down-modulates
both the mRNA levels and protein expression of IL-8 and
ICAM-1, stimulated by PAO1 [8], the effect of miglustat was
studied in the same experimental model in IB3-1 and CuFi-1
cells using quantitative real-time RT-PCR as analytical
methodology. Miglustat significantly inhibits the PAO1 induced
accumulation of both IL-8 (pb0.0001) and ICAM-1(pb0.0009)
mRNAs in IB3-1 cells (Fig. 3A and B). Also in CuFi-1 cells
miglustat significantly inhibits IL-8 (pb0.003) and ICAM-1
(pb0.03) mRNA accumulation (Fig. 3C and D). Consideringclear extracts were isolated from uninfected and PAO1 infected cells. Increasing
P-1 target oligonucleotides and protein/DNA complexes (arrowed) analysed by
has no major effect on NF-κB and AP-1 overall binding activity. IB3-1 cells were
panel) of 200 μMmiglustat for 24 h and then infected or not with 50 CFU/cell of
re isolated and increasing amounts of them (μg/reactions) were mixed with NF-
formed. In the right side of panels B and C quantitative analysis of DNA–protein
io-Rad Gel-Doc densitometry system is shown. The results reported represent
l cells (−) (average±SD from three independent experiments). Open bars=no
iglustat.
Fig. 6. Both miglustat and NB-DGJ reduce the PAO1 stimulated IL-8 mRNA
expression in CF and non-CF bronchial cells. Cells were incubated with miglustat
orNB-DGJ (200μM) for 24h as described in Fig. 3. ThemRNA induction (relative
to non-infected cells) is obtained by comparing the ratio IL-8/GAPDH between
non-infected and infected cells. Results are expressed as mean±SEM of duplicate
wells. Representative of 3(A), 4(B) and 5(C) independent experiments in duplicate
are shown.
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sustained in the advanced stages by non-motile P. aeruginosa
growing in biofilms, we tested the effect of a potent pro-
inflammatory stimulus deriving from the bronchial lumina of
CF patients undergoing lung transplantation [18–19]. Pooled
supernatants of mucopurulent material (SMM), obtained from
human CF lungs infected with P. aeruginosa and S. aureus
[18–19], were tested in IB3-1 cells upon treatment with
miglustat. The significant inhibition of the expression of IL-8
stimulated by SMM, shown in Fig. 4, strengthens the potential
anti-inflammatory effect of miglustat in reducing the P.
aeruginosa-dependent transcription of two critical genes
involved in leukocyte chemotaxis, such as IL-8 and ICAM-1.
3.3. DNA-binding activity of NF-κB and AP-1 by P. aeruginosa
in cells treated with miglustat
The inhibitory effect observed on IL-8 and ICAM-1
transcription in CF airway epithelial cell lines opens the
possibility that miglustat could intervene in the signalling
cascade between the receptors recognized by P. aeruginosa and
the transcription of IL-8 and ICAM-1, besides correcting
F508del-CFTR. Attention was therefore drawn on the tran-
scription factors NF-κBNF-kB and AP-1, which play a central
role in the immune response to P. aeruginosa infection in
respiratory epithelial cells [29] and have already demonstrated
to be activated in IB3-1 and CuFi-1 cells upon infection with
PAO1 [8]; accordingly, putative target consensus sequences of
these two transcription factors have been found within the
promoter sequences of both IL-8 and ICAM-1 genes (TESS
software analysis) (www.cbill.upenn.edu/cgi_bin/tess/tess). In
order to determine whether miglustat treatment modulates the
overall NF-κBNF-kB and AP-1 binding activity the experiment
shown in Fig. 5 was performed. IB3-1 cells were cultured in the
absence or in the presence of miglustat and then infected or not
with PAO1 for 2 h. Nuclear extracts were isolated, increasing
amounts of them were mixed with NF-κBNF-kB and AP-1
target 32P-labelled oligodeoxynucleotides and EMSA was
performed. The results clearly allow these conclusions:
(a) both NF-κBNF-kB and AP-1 binding activity significantly
increases following P. aeruginosa infection of IB3-1 cells
(pb0.05) (see data reported in Fig. 5A) and (b) no significant
major alteration of this binding activity occurs in both
uninfected or PAO1 infected cells treated with miglustat (see
data reported in Fig. 5, B and C). These results were
consistently obtained in three independent experiments. There-
fore miglustat has no major effect on overall binding activity of
the transcription factors NF-κBNF-kB and AP-1.
3.4. Effect of NB-DGJ on PAO1 stimulated IL-8 MRNA
expression in IB3-1, CuFi-1 and NuLi-1 cells
To verify whether the anti-inflammatory effect of miglustat
observed in IB3-1 and CuFi-1 cells might be related to the
correction of F508del-CFTR function, cells were also treated
with NB-DGJ, which does not restore CFTR-dependent Cl-
transport (Fig. 1). As shown in Fig. 6A and B, also NB-DGJsignificantly reduces the expression of IL-8 mRNA stimulated
by PAO1 in IB3-1 (pb0.003) and CuFi-1 cells (pb0.04). These
experiments were extended to NuLi-1 cells, which express wild
type CFTR protein. As shown in Fig. 6C miglustat significantly
decreases the amount of IL-8 mRNA also in NuLi-1 cells
(pb0.02). Moreover, NB-DGJ produces a significant inhibition
of the transcription of IL-8 stimulated by PAO1 (pb0.04)
although to a lower extent of that obtained with miglustat
(pb0.03). On the whole, these results indicate that the anti-
Fig. 8. Miglustat and NB-DGJ reduce the expression of IL-8 mRNA stimulated
by PAO1, or TNF alpha or IL-1 beta in IB3-1 and CuFi-1 cell lines. Cells were
incubated for 24 h with miglustat or NB-DGJ (200 μM) and then infected with
PAO1 as above described or stimulated with TNF alpha (10 ng/ml) or IL-1 beta
(50 ng/ml) for 4 h. Stimulated IL-8 mRNA expression was calculated as
indicated in the legend of Fig. 3 and it is expressed as % of untreated cells. A. In
untreated IB3-1 cells the stimulated IL-8 mRNA expression was 407±80 by
PAO1, 51±6 by TNF alpha and 148±15 by IL-1 beta (n=4). B. In untreated
CuFi-1 cells the stimulated IL-8 mRNA expression was 52±13 by PAO1, 6±1
by TNF alpha and 9±1 by IL-1 beta (n=4). Representative of 2 independent
experiments in duplicate are shown.
Fig. 7. Miglustat does not reduce the binding of PAO1 to IB3-1 and CuFi-1 cells.
500,000 IB3-1 (A) or CuFi-1 (B) cells on Petri dishes, in duplicate, were treated
for 24 h with 200 μM miglustat and then washed with PBS before performing
adhesion experiments. Different amounts of 35S-PAO1, expressed as CFU/well,
were added to the wells and incubated as described in Materials and methods
section. Data reported in the figure are the specific binding calculated by
subtracting counts obtained in the presence of 100-fold excess of non-labelled
PAO1 and are expressed as CFU/well. Representative of two independent
experiments are reported in the figure.
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correction of F508del-CFTR in IB3-1 and CuFi-1 cells.
3.5. Adherence of PAO1 to IB3-1 and CuFi-1 cells treated with
miglustat
Many pathogenic microorganisms use glycoconiugate
receptors to establish contact with the host tissues [30] and
pharmacological agents that inhibit the biosynthesis of these
receptors may have a major impact on the pathogenesis of
infection. Miglustat was shown to decrease the GSL content, to
inhibit the P-fimbriated bacterial attachment and, as a
consequence, to impair the mucosal inflammatory response in
mice [31]. P. aeruginosa flagellin can interact with both Toll-
like receptor 5 (TLR5) and the cell surface glycolipid,
asialoGM1, to activate the innate immune response [29].
Therefore the anti-inflammatory effect of miglustat observed in
IB3-1 and CuFi-1 cells could reflect the reduced expression of
the glycolipid receptors for PAO1. To evaluate this possibility
the adherence of metabolically labelled [35S] methionine-PAO1
was measured in IB3-1 and CuFi-1 cells, treated or not with
miglustat. Fig. 7A and B show a dose dependent increase of thePAO1 binding to the cells and no significant differences due to
the treatment with miglustat. These results indicate that
incubation with miglustat for 24 h does not affect the adherence
of PAO1 to IB3-1 and CuFi-1 cells, suggesting that the huge
inhibition of P. aeruginosa-dependent IL-8 and ICAM-1
transcription after treatment with miglustat is not dependent
upon reduction of bacterial-host cell interactions.
3.6. Effect of miglustat and NB-DGJ on the expression of IL-8
mRNA stimulated by PAO1, TNF alpha or IL-1 beta in IB3-1
and CuFi-1 cells
The results shown so far indicate that miglustat and NB-DGJ
have an anti-inflammatory effect in bronchial epithelial cells,
suggesting that they could inhibit the transmembrane signalling
between the receptors for pathogens and the transcription of the
inflammatory genes. To obtain preliminary insights on which
transduction pathway is inhibited by miglustat and NB-DGJ, the
expression of IL-8 mRNA stimulated by either PAO1 or the pro-
inflammatory cytokines TNF alpha and IL-1 beta, was studied
both in IB3-1 and in CuFi-1 cells. As depicted in Fig. 8A,
miglustat and NB-DGJ significantly inhibit the expression of
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TNF alpha or IL-1 beta , in IB3-1 cells. Fig. 8B confirms these
findings also in CuFi-1 cells. Interestingly, miglustat produces a
significantly stronger reduction of IL-1 beta elicited IL-8
mRNA expression than that given by NB-DGJ, in IB3-1 and
CuFi-1 cells, whereas no differences are observed both upon
infection with PAO1 and induction by TNF alpha. Therefore,
miglustat and NB-DGJ inhibit the pro-inflammatory signalling
downstream the receptors for PAO1 and for these pro-
inflammatory cytokines.
4. Conclusions
We recently demonstrated that miglustat, an inhibitor of the
ER alpha-1,2-glucosidase, restores F508del-CFTR function in
human nasal epithelial JME/CF15 cells by preventing the
interaction between F508del-CFTR and calnexin [17]. Folding
and trafficking of proteins to their correct cellular location
depend on molecular chaperones which can have different
effects on each particular substrate and particular cell type [32].
As a consequence, the effectiveness of small correctors of
protein trafficking defect may depend on the cellular environ-
ment and may be cell type specific. The rescue of CFTR
function by miglustat has been observed in different cells, such
as nasal JME/CF15, tracheal gland serous CFKM4, pancreatic
duct CFPAC-1 cell lines, intestinal cells of F508del-CFTR mice
[17]. Here we report a correcting effect in the CF bronchial IB3-
1 and CuFi-1 cells (Figs. 1 and 2), although we observed a lack
of rescue of CFTR function in IB3-1 cells treated with miglustat
for 24 h (Fig. 1B). Experience from the newly discovered
F508del-CFTR correctors starts indicating that the potency of
action can be quite different, or sometimes even absent, when
tested in different cell models [32]. In respect to miglustat, it
should be recalled that it corrects F508del-CFTR by inhibiting
the α-glucosidase of the ER [17], an effect which can vary upon
the cells line model and the culture conditions. Moreover, CuFi-
1 cells are homozygous for the F508del-CFTR mutation
whereas IB3-1 cells are compound heterozygous for the
F508del-CFTR mutation (genotype F508del/W1282X). As the
amount of F508del proteins in IB3-1 cells may be quite different
compared to that of CuFi-1 cells this may also contribute to the
variability of the correcting effect, which anyway requires
further investigation.
In this study we have shown that miglustat: i) is a corrector of
F508del-CFTR function in CF bronchial IB3-1 and CuFi-1
cells; ii) has an anti-inflammatory effect in bronchial cells
independently of the correction of F508del-CFTR; iii) has no
effect on NF-κB and AP1 overall binding activity; iv) inhibits
the pro-inflammatory signalling downstream both the receptors
for pathogens and key pro-inflammatory cytokines.
Therefore, besides confirming the correction of F508del-
CFTR function, we have demonstrated that miglustat reduces
the inflammatory response elicited by P. aeruginosa or SMM in
CF bronchial IB3-1 and CuFi-1 cells (Figs. 3 and 4), supporting
the hypothesis that the pharmacological modulation of CFTR
defect may reduce the excessive lung inflammatory response in
CF cells, consistent with previous findings showing an anti-inflammatory effect of the corrector MPB-07 [8]. However, also
the galactose analog of miglustat, NB-DGJ, which is not a
corrector of F508del-CFTR function, reduces the inflammatory
response in CF cells and both the compounds have an anti-
inflammatory effect in non-CF bronchial NuLi-1 cells (Fig. 6).
Therefore, althoughmiglustat rescues functional F508del-CFTR
in CF bronchial cells, it affects the inflammatory response to P.
aeruginosa through a mechanism which, at least partly, is
independent of the correction of F508del-CFTR function.
How this occurs is a matter of speculation. Both analogues,
miglustat and NB-DGJ, are inhibitors of the first step in GSL
biosynthesis which is the transfer of glucose to ceramide by the
ceramide-specific glucosyl-transferase (CerGlcT) [30], whereas
miglustat, but not NB-DGJ, also inhibits ER alpha-glucosidase
[16]. The fact that correction of F508del-CFTR function is
obtained in cells treated with miglustat but not with NB-DGJ,
supports that the correcting effect is specifically related to ER
alpha-glucosidase inhibition, thus preventing the interaction of
F508del-CFTR with calnexin [17]. On the other hand the anti-
inflammatory effect observed in cells treated with either miglustat
or NB-DGJ suggests a mechanism involving the inhibition of
CerGlcT, an activity shared by both compounds. Nevertheless,
depending on cell type and pro-inflammatory stimulus, miglustat
seems to be more effective than NB-DGJ (Figs. 3C and 8). Thus,
also ER alpha-glucosidase could play a role in pro-inflammatory
signaling. CerGlcT is crucial for the synthesis of GSL and it is the
target for treating GSL lysosomal storage disease in the
therapeutic approach termed substrate reduction therapy [16].
Gaucher disease is the most frequently occurring GSL storage
disease, characterized by accumulation of glucosylceramide
causing heterogeneous clinical features, among which sustained
inflammatory reaction associated with elevated levels of pro-
inflammatory cytokines [33]. It has been suggested that GSLmay
act as signalling molecule to dysregulate the immune system in
Gaucher disease [34]. Interestingly, mouse models of GSL
storage diseases treated by substrate reduction therapy with
miglustat, display a marked reduction in systemic inflammation
[35], strengthening the link between the accumulation ofGLS and
the extent of the inflammatory response. Very importantly, the
accumulation of the sphingolipid ceramide has been recently
identified as one of the key regulators of inflammation and
infection in CF airways [36]. We can thus argue that miglustat
reduces the inflammatory response by interfering with ceramide
signalling. The transcription factors NF-κBNF-kB and AP-1 play
a central role in the immune response toP. aeruginosa infection in
respiratory epithelial cells [29]. Interestingly, an alternative
pathway, independent of NF-κB, operating through prostaglandin
E2 receptor, has been demonstrated to regulate IL-8 secretion in
IB3-1 cells [37]. A likely inhibition of the overall binding activity
of NF-κBNF-kB and AP-1 by miglustat has been ruled out from
the data reported in Fig. 5, suggesting that it could interfere with
other pathways in signal transduction. Future studies on the
potential effect of miglustat on the complex array of transcription
factors regulating IL-8, ICAM-1 and other genes of the innate
immune response are needed to ascertain this point.
The anti-inflammatory effect of miglustat and NB-DGJ
could reflect the reduced expression of the glycolipid receptors
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as a consequence of the inhibition of CerGlcT activity. Here we
show that miglustat does not reduce the adherence of P.
aeruginosa to the IB3-1 cells (Fig. 7), thus making unlikely that
the anti-inflammatory effect of miglustat is due to interference
with the receptors for P. aeruginosa. Moreover, since miglustat
strongly reduces the pro-inflammatory signals elicited also by
TNF alpha and IL-1 beta (Fig. 8), these compounds could
possibly modulate directly or indirectly the activity of some of
the different kinases or adapters downstream the receptors for
pathogens, in common with TNF alpha and IL-1 beta receptors
through a mechanism that needs further investigation. From the
practical point of view, the results presented in this paper show
that miglustat has two therapeutically relevant effects in CF
cells: it rescues the F508del-CFTR function and reduces the
inflammatory response to P. aeruginosa. Interestingly, both
correction of the cystic fibrosis defect and inhibition of anti-
inflammatory responses are of great importance in the therapy
of CF patients. Accordingly, a drug displaying these two effects
deserves great attention. Furthermore, the effects of miglustat
on human subjects are well known. In fact, miglustat is an orally
bioavailable drug approved in Europe and USA for the
treatment of Gaucher disease and other GSL storage diseases.
Human studies show that it is well tolerated at 100 or 300 mg
once or three times daily [38]. The pharmacokinetic properties
of miglustat, studied at the dosage used in the treatment of type
1 Gaucher's disease [15] indicate that the drug is rapidly
absorbed after oral administration, with a peak plasma
concentration of 0.86 μM/mL at 2.5 h. In clinical trials, for a
dosage of 100 mg three times daily, steady-state plasma
concentration of 1.5 μM/mL was attained within 4–6 weeks
[15,39]. Although studies in murine models indicate that lung
tissue concentrations reach equimolar levels with those in
plasma [40], to the best of our knowledge no data on human
lung tissue concentrations have been studied after oral
treatment. Therefore, further investigation in animal models
will be necessary to start understanding the effective anti-
inflammatory concentration in vivo. Moreover, analysis of
markers of inflammation in CF patients undergoing clinical
trials with oral miglustat as a CFTR corrector (http://
clinicaltrials.gov/) will likely help elucidating this important
issue, which is difficult to predict simply from in vitro studies.
All this considered, miglustat may represent a promising
candidate for the pharmacotherapy of CF and an interesting
research tool to investigate the immune response of airway
cells.
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